ABBV logo

ABBV
Abbvie Inc

32,049
Mkt Cap
$403.22B
Volume
103.00
52W High
$244.81
52W Low
$163.81
PE Ratio
108.62
ABBV Fundamentals
Price
$229.00
Prev Close
$228.68
Open
$228.99
50D MA
$220.13
Beta
0.33
Avg. Volume
5.51M
EPS (Annual)
$2.39
P/B
-2,203.19
Rev/Employee
$1.02M
Loading...
Loading...
News
all
press releases
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
AbbVie (ABBV) concluded the recent trading session at $228.68, signifying a -1.17% move from its prior day's close.
Zacks·2d ago
News Placeholder
More News
News Placeholder
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Zacks·2d ago
News Placeholder
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Zacks·2d ago
News Placeholder
This 3 Stocks Portfolio Provides Monthly Income
Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.
Zacks·2d ago
News Placeholder
Top Stock Reports for Apple, Meta Platforms & JPMorgan
Apple's Services surge, Meta's AI push, and JPMorgan's strong capital markets results headline today's top stock research picks.
Zacks·3d ago
News Placeholder
Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks
The Investment Committee give you their top stocks to watch for the second half...
CNBC Television-YouTube·3d ago
News Placeholder
The Confidence Project by BOTOX Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
The Confidence Project by BOTOX Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients The Confidence Project by BOTOX Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients...
PR Newswire·3d ago
News Placeholder
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Zacks·4d ago
News Placeholder
Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic
Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs.
Stocktwits·7d ago
News Placeholder
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin PR Newswire NORTH CHICAGO, Ill., Oct. 17, 2025...
PR Newswire·7d ago

Latest ABBV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.